2014 – A Good Year for Rare Disease Registries
What a year 2014 has been in the area of rare disease and rare disease registries. It was an active year for rare disease registries. The number of rare disease patient registries continued to grow - from just 500 in 2011 to over 620 in 2014. Here are some of the highlights from 2014.
Raising Awareness of Rare Diseases
The Ice bucket challenge for ALS/MND swept the globe raising billions in cash and raising awareness of rare diseases. Thousands of events were held in over 80 countries worldwide to celebrate Rare Disease Day in February.
Legislative Changes in Support of Rare Disease Research in 2014
The European Medicines Agency announced greater fee reductions for large companies planning to market orphan drugs for rare diseases in the EU, as a further incentive for orphan medicinal product development. It also confirmed current financial assistance for SMEs.
A bill passed with commencement in 2016 means that pharmaceutical companies and academic researchers will have to post results from all their European clinical trials in a publicly accessible database, increasing transparency and trust. These trials must be registered in a central database and a summary of results positive or negative must be uploaded within one year after the end of the trial.
The much anticipated new European Regulation on Clinical Trials was finally published in May. Under the new regulation, multinational clinical trials will be easier to conduct, facilitating cross-border collaboration for larger clinical trials.
The much awaited ontology of rare diseases was released in February, it provides a structured vocabulary for rare diseases, capturing relationships between diseases, genes and other pertinent features, in a language directly understandable by computers. Ireland and Scotland adopted their National Rare Disease plans while Spain updated its plan.
The number of rare disease patient registries continued to grow from just 500 in 2011 to over 620 in 2014.
EPIRARE finalised its recommendations which state that all registries should be web-based and inter-operable throughout Europe. In addition, the EPIRARE committee has proposed that new and existing registries use a core set of common data elements.
and much much more.
We have also seen a big increase in interest in linking registries to genetic databases.
We'll shortly announce EPIRARE 100, a free patient registry where any patient organization will be able to set up a registry with up to 100 patients based on the EPIRARE minimum data set. This will be sufficient for rare diseases with low prevalence and for regional disease registries. For larger patient populations this registry can be used as a “Proof of Concept”.
The EPIRARE 100 registry is based on the same software and secured hosting services are our commercial software. There will be no time limit associated with the free version and we hope that this will replace the “spreadsheet hell” that many patient organizations were forced in the past to use.
So I'm hoping that there will be more rare disease registries this year because as one patient advocate recently said “registries are the cement of clinical research”.
The best of luck for 2015.
Learn more about our work in the rare disease registries space.
Software Maintenance Management Planning
Combining the development efforts and the ongoing maintenance of your software is key to ensuring that you have a robust and constantly improving and evolving solution.
Having a software maintenance plan is just as important as the initial development. Professionally managed maintenance allows for the continual improvement and adaptation to changing business needs and technological advancements.Read More
Patient Registry Data and General Data Protection Regulation
GDPR stands for General Data Protection Regulation. First brought into effect in 2018, all businesses have been affected by the EU regulation worldwide. In this article, we will highlight what the regulation entails, key terms/items from the legislation, it’s importance in the modern world, how it measures up against other regulations and finally, how we as a company ensure our compliance.Read More
OpenApp supports Metachromatic Leukodystrophy Disease MLD Research
To celebrate Rare Disease Day 2023, which takes place on the 28th of February, we are changing our colours and showing our support for the Metachromatic Leukodystrophy Disease (MLD) Support Association UK. OpenApp have been working MLD support Association UK for many years under our Rare100 CSR scheme, a Corporate Social Responsibility (CSR) initiative run in 2018.Read More
189-193 Parnell Street,
Copyright © 2023 OpenApplications All rights reserved.
OpenApplications Consulting Ltd. Registered in Ireland No. 355595